Contact your healthcare provider promptly if you experience: Persistent gastrointestinal symptoms : Severe nausea, vomiting, or diarrhea lasting more than 24 hours, particularly if accompanied by signs of dehydration (decreased urination, dizziness, dry mouth) Abdominal pain : Severe or persistent pain, especially in the upper abdomen radiating to the back, which may indicate pancreatitis Gallbladder symptoms : Right upper quadrant pain, particularly after meals, with or without fever and jaundice Hypoglycemia : Symptoms including shakiness, sweating, confusion, rapid heartbeat, or difficulty concentrating, especially if taking tirzepatide with insulin or sulfonylureas Kidney problems : Decreased urination, swelling in legs or feet, unusual fatigue, or confusion Mental health changes : New or worsening depression, suicidal thoughts, or unusual changes in mood or behavior Pregnancy : If you become pregnant or are planning pregnancy while taking tirzepatide, especially for weight management Seek emergency medical attention for: Severe allergic reactions : Difficulty breathing, facial or throat swelling, severe rash, or rapid heartbeat Severe abdominal pain : Particularly if accompanied by vomiting and inability to tolerate oral intake Vision changes : Sudden vision loss or blurred vision, which may indicate diabetic retinopathy complications Thyroid concerns : A lump or swelling in the neck, hoarseness, difficulty swallowing, or persistent cough Patients should maintain regular follow-up appointments for monitoring of glycemic control, weight, and potential adverse effects
I have to get healthy. Lang, of Winfield, Butler County, decided to start taking the prescription drug Ozempic in January
Pyridoxine is one of the first supplements recommended during early pregnancy for morning sickness management, so having adequate B6 stores from the compound could be protective during the transition period
Alcohol and GLP-1 drops Drinking alcohol while on semaglutide or tirzepatide is a topic that generates significant debate
Ayrca 2024'te Endokrin Dernei'nin toplantsnda sunulan bir almada da 30 kiilik hasta grubundan semaglutid alanlarn, farkl tatlara kar daha fazla hassasiyetleri olduu grlmt
